Literature DB >> 22495453

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.

Seung Tae Kim1, Hoiseon Jeong, Ok Hee Woo, Jae Hong Seo, Aeree Kim, Eun Sook Lee, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Kyong Hwa Park.   

Abstract

BACKGROUND: The balance in the immune system between immune surveillance against non-self-antigens and tolerance of self-antigens is known to be associated with the prognosis of breast cancer patients. However, immunologic signals in tumor microenvironment according to biological characteristics of cancer cells have not been clearly elucidated. CD4(+) T cells, CD8(+) T cells, and forkhead box P3-positive (Foxp3) regulatory T cells (Tregs) are the main keys for immune surveillance and tolerance, respectively. We evaluated the correlations between the immunologic balance and tumor characteristics and their impact on recurrence. PATIENTS AND METHODS: CD8(+) T cells and Foxp3(+) Tregs were detected by immunohistochemistry using the paraffin-embedded tumor samples from the 72 patients with early stage (I to III) breast cancer. Clinicopathologic data including tumor size and grade, lymph node metastasis, stage, patient's age, expression status of estrogen receptor (ER), progesterone receptor, p53, Ki-67, and human epidermal growth factor receptor-2/neu, and recurrence were reviewed.
RESULTS: The decreased number of CD8(+) T cells was significantly associated with tumors with lymph node metastasis (P=0.027), higher stage (stage III, P=0.013), and immunopositivity of Ki-67 (P=0.026). In contrast, the increased number of Foxp3(+) Tregs was significantly correlated with tumors with lymph node metastasis (P=0.027), immunopositivity for p53 (P=0.026), and positive for Ki-67 (P<0.001). There were significant correlations between the increased Foxp3(+) Treg/CD4(+) T-cell ratio and lymph node metastasis (P=0.011), the expression of ER (P=0.023), and immunopositivity of p53 (P=0.031) and Ki-67 (P= 0.003). Of note, lower Foxp3(+) Treg/CD4(+) T-cell ratio was significantly associated with triple-negative breast cancer (P=0.004). Disease-free survival of analyzed patients was significantly associated with the number of Foxp3(+) Tregs (dichotomized by a cutoff point of 17, P= 0.014) only. Univariate analysis indicated that tumor grade (P=0.017), the expression of ER (P=0.032), and non-triple-negative breast cancer (P=0.022) were independent prognostic factors for disease-free survival.
CONCLUSIONS: Our data showed that lymph node metastases, immunopositivity of p53 and Ki67, and non-triple-negative tumors were associated with high regulatory T-cell infiltration. The role of immunologic balance as a prognostic marker for recurrence must be evaluated more clearly in the future study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22495453     DOI: 10.1097/COC.0b013e3182467d90

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  50 in total

Review 1.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

2.  Human adipose-derived stromal/stem cells induce functional CD4+CD25+FoxP3+CD127- regulatory T cells under low oxygen culture conditions.

Authors:  Trivia P Frazier; James B McLachlan; Jeffrey M Gimble; Hugh A Tucker; Brian G Rowan
Journal:  Stem Cells Dev       Date:  2014-03-11       Impact factor: 3.272

3.  IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses.

Authors:  Rosa M Santana Carrero; Figen Beceren-Braun; Sarai C Rivas; Shweta M Hegde; Achintyan Gangadharan; Devin Plote; Gabriel Pham; Scott M Anthony; Kimberly S Schluns
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-26       Impact factor: 11.205

Review 4.  Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology?

Authors:  Ashleigh Unsworth; Robin Anderson; Kara Britt
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-07-02       Impact factor: 2.673

Review 5.  The immune response in cancer: from immunology to pathology to immunotherapy.

Authors:  Nicolas A Giraldo; Etienne Becht; Yann Vano; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2015-06-16       Impact factor: 4.064

6.  Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging.

Authors:  Simon Lavotshkin; John R Jalas; Hitoe Torisu-Itakura; Junko Ozao-Choy; Ji Hey Lee; Myung Shin Sim; Alexander Stojadinovic; Zev Wainberg; Carlo B Bifulco; Bernard A Fox; Anton J Bilchik
Journal:  J Gastrointest Surg       Date:  2015-03-26       Impact factor: 3.452

7.  Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.

Authors:  Ashley Cimino-Mathews; Xiaobu Ye; Alan Meeker; Pedram Argani; Leisha A Emens
Journal:  Hum Pathol       Date:  2013-05-21       Impact factor: 3.466

8.  Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer.

Authors:  Anqing Zhu; Huizi Sha; Shu Su; Fangjun Chen; Jia Wei; Fanyan Meng; Yang Yang; Juan Du; Jie Shao; Fuzhi Ji; Chong Zhou; Zhengyun Zou; Xiaoping Qian; Baorui Liu
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

Review 9.  Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.

Authors:  Xiaohui Wang; Zhiqiang Wu; Wei Qiu; Ping Chen; Xiang Xu; Weidong Han
Journal:  Front Med       Date:  2020-08-13       Impact factor: 4.592

10.  Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma.

Authors:  Shali Zhang; Hideki Fujita; Hiroshi Mitsui; Valerie R Yanofsky; Judilyn Fuentes-Duculan; Julia S Pettersen; Mayte Suárez-Fariñas; Juana Gonzalez; Claire Q F Wang; James G Krueger; Diane Felsen; John A Carucci
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.